Role of <scp>TP53</scp> Mutations and <scp>EGFR</scp> Amplification in Risk Stratification of Early‐Stage <scp>EGFR</scp>‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker
Specific subtypes of TP53 mutations and EGFR amplification are important prognostic markers in early-stage NSCLC. IHC offers a practical surrogate for genetic testing, aiding in risk stratification and guiding adjuvant therapy decisions for high-risk patients. Larger validation studies are warranted.
Authors
- Kyo Young Lee (ORCID: https://orcid.org/0000-0001-9954-8583)
- Seok Whan Moon (ORCID: https://orcid.org/0000-0003-3348-6011)
- Yeoun Eun Sung (ORCID: https://orcid.org/0000-0002-9408-0085)
- Meejeong Kim (ORCID: https://orcid.org/0000-0002-1232-8439)
- Gyeong Sin Park
Institutions
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1111/1759-7714.70058
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04